Azenta acquires UK Biocentre for GBP 20.5M to expand European biorepository footprint

Azenta, Inc.

Total consideration of GBP 20.5M net of cash, including up to GBP 1.8M contingent milestone payments.
UK Biocentre generated approx GBP 15.3M revenue in twelve months ended Sep 30, 2025.
Deal expected to be dilutive to FY2026 Adj EBITDA margin by ~35bps, accretive to FY2027/2028 revenue growth and margin.
UK Biocentre will operate as European hub, adding automated high-throughput capacity and BioArc™ Ultra deployment.
Conference call to discuss transaction scheduled for March 10, 2026 at 10:00 am ET.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Azenta, Inc. entered into Share Purchase Agreement with UK Biocentre Limited valued at GBP 20.5 million (effective 2026-03-04).

Action: entry
Agreement: asset purchase
Counterparty: UK Biocentre Limited
Value: GBP 20.5 million
Effective: 2026-03-04

Exact text from the filing

On March 4, 2026, Azenta UK Ltd., a wholly owned subsidiary of Azenta, Inc. (“Azenta” or the “Company”) entered into a definitive Share Purchase Agreement (“Agreement”) under which Azenta UK Ltd. acquired all the issued and outstanding share capital of UK Biocentre Limited (“UK Biocentre”), a provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Azenta, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-006821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.